RNAC Overview

Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Wall Street analysts forecast RNAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAC is35.00 USD with a low forecast of 16.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cartesian Therapeutics Inc revenue for the last quarter amounts to 78.00K USD, decreased -92.91

Cartesian Therapeutics Inc. EPS for the last quarter amounts to -1.46 USD, increased 114.71

Cartesian Therapeutics Inc (RNAC) has 75 emplpoyees as of June 12 2026.

Today RNAC has the market capitalization of 218.30M USD.